644 related articles for article (PubMed ID: 36010607)
1. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Drakulic D; Schwirtlich M; Petrovic I; Mojsin M; Milivojevic M; Kovacevic-Grujicic N; Stevanovic M
Cells; 2022 Aug; 11(16):. PubMed ID: 36010607
[TBL] [Abstract][Full Text] [Related]
2. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Alafate W; Xu D; Wu W; Xiang J; Ma X; Xie W; Bai X; Wang M; Wang J
J Exp Clin Cancer Res; 2020 Nov; 39(1):239. PubMed ID: 33176854
[TBL] [Abstract][Full Text] [Related]
3. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
5. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).
Jin J; Grigore F; Chen CC; Li M
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013362
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy.
Wang S; Gu S; Chen J; Yuan Z; Liang P; Cui H
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672496
[TBL] [Abstract][Full Text] [Related]
8. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).
Khabibov M; Garifullin A; Boumber Y; Khaddour K; Fernandez M; Khamitov F; Khalikova L; Kuznetsova N; Kit O; Kharin L
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35445737
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
12. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Pellecchia S; De Martino M; Esposito F; Quintavalle C; Fusco A; Pallante P
Cell Cycle; 2021 Apr; 20(7):716-729. PubMed ID: 33734003
[TBL] [Abstract][Full Text] [Related]
13. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
14. Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme.
Precilla DS; Kuduvalli SS; Purushothaman M; Marimuthu P; Muralidharan AR; Anitha TS
Curr Mol Pharmacol; 2022; 15(2):338-360. PubMed ID: 33881978
[TBL] [Abstract][Full Text] [Related]
15. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
16. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Ma Z; Cai S; Xiong Q; Liu W; Xia H; Zhu Z; Huang Z; Yan X; Wang Q
Apoptosis; 2022 Feb; 27(1-2):80-89. PubMed ID: 35037107
[TBL] [Abstract][Full Text] [Related]
17. Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Wang J; Zuo J; Wahafu A; Wang MD; Li RC; Xie WF
CNS Neurosci Ther; 2020 Mar; 26(3):297-308. PubMed ID: 31318172
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways.
Bagherian A; Mardani R; Roudi B; Taghizadeh M; Banfshe HR; Ghaderi A; Davoodvandi A; Shamollaghamsari S; Hamblin MR; Mirzaei H
J Mol Neurosci; 2020 Oct; 70(10):1471-1483. PubMed ID: 32666415
[TBL] [Abstract][Full Text] [Related]
19. Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma.
Lin IC; Chang CH; Chong YB; Kuo SH; Cheng YW; Lieu AS; Tseng TT; Lin CJ; Tsai HP; Kwan AL
Cells; 2023 Oct; 12(19):. PubMed ID: 37830634
[TBL] [Abstract][Full Text] [Related]
20. Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
Salerno S; Barresi E; Baglini E; Poggetti V; Da Settimo F; Taliani S
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
